79 results on '"Inositol deficiency"'
Search Results
2. Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies.
- Author
-
Lepore E, Lauretta R, Bianchini M, Mormando M, Di Lorenzo C, and Unfer V
- Subjects
- Animals, Biological Transport, Biosynthetic Pathways, Dietary Supplements, Gastrointestinal Absorption, Gastrointestinal Microbiome, Humans, Inositol administration & dosage, Kidney metabolism, Carbohydrate Metabolism, Inositol deficiency, Inositol metabolism
- Abstract
Inositols are natural molecules involved in several biochemical and metabolic functions in different organs and tissues. The term "inositols" refers to five natural stereoisomers, among which myo-Inositol (myo-Ins) is the most abundant one. Several mechanisms contribute to regulate cellular and tissue homeostasis of myo-Ins levels, including its endogenous synthesis and catabolism, transmembrane transport, intestinal adsorption and renal excretion. Alterations in these mechanisms can lead to a reduction of inositols levels, exposing patient to several pathological conditions, such as Polycystic Ovary Syndrome (PCOS), hypothyroidism, hormonal and metabolic imbalances, like weight gain, hyperinsulinemia, dyslipidemia, and metabolic syndrome. Indeed, myo-Ins is involved in different physiological processes as a key player in signal pathways, including reproductive, hormonal, and metabolic modulation. Genetic mutations in genes codifying for proteins of myo-Ins synthesis and transport, competitive processes with structurally similar molecules, and the administration of specific drugs that cause a central depletion of myo-Ins as a therapeutic outcome, can lead to a reduction of inositols levels. A deeper knowledge of the main mechanisms involved in cellular inositols depletion may add new insights for developing tailored therapeutic approaches and shaping the dosages and the route of administration, with the aim to develop efficacious and safe approaches counteracting inositols depletion-induced pathological events.
- Published
- 2021
- Full Text
- View/download PDF
3. Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation.
- Author
-
Pani A, Giossi R, Menichelli D, Fittipaldo VA, Agnelli F, Inglese E, Romandini A, Roncato R, Pintaudi B, Del Sole F, and Scaglione F
- Subjects
- Animals, Cholesterol metabolism, Female, Glutathione Peroxidase metabolism, Humans, Inositol administration & dosage, Insulin Resistance, Lipid Peroxidation, Liver metabolism, Male, Non-alcoholic Fatty Liver Disease complications, Postprandial Period, Randomized Controlled Trials as Topic, Treatment Outcome, Triglycerides metabolism, Dietary Supplements, Inositol analogs & derivatives, Inositol deficiency, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease therapy
- Abstract
Liver lipid accumulation is a hallmark of non-alcoholic fatty liver disease (NAFLD), broadly associated with insulin resistance. Inositols (INS) are ubiquitous polyols implied in many physiological functions. They are produced endogenously, are present in many foods and in dietary supplements. Alterations in INS metabolism seems to play a role in diseases involving insulin resistance such as diabetes and polycystic ovary syndrome. Given its role in other metabolic syndromes, the hypothesis of an INS role as a supplement in NAFLD is intriguing. We performed a systematic review of the literature to find preclinical and clinical evidence of INS supplementation efficacy in NAFLD patients. We retrieved 10 studies on animal models assessing Myoinosiol or Pinitol deficiency or supplementation and one human randomized controlled trial (RCT). Overall, INS deficiency was associated with increased fatty liver in animals. Conversely, INS supplementation in animal models of fatty liver reduced hepatic triglycerides and cholesterol accumulation and maintained a normal ultrastructural liver histopathology. In the one included RCT, Pinitol supplementation obtained similar results. Pinitol significantly reduced liver fat, post-prandial triglycerides, AST levels, lipid peroxidation increasing glutathione peroxidase activity. These results, despite being limited, indicate the need for further evaluation of INS in NAFLD in larger clinical trials.
- Published
- 2020
- Full Text
- View/download PDF
4. Generation and characterization of thiol-deficient Mycobacterium tuberculosis mutants.
- Author
-
Sao Emani C, Williams MJ, Van Helden PD, Taylor MJC, Carolis C, Wiid IJ, and Baker B
- Subjects
- Bacterial Proteins chemistry, Bacterial Proteins genetics, Mutation, Oxidative Stress genetics, Sulfhydryl Compounds, Cysteine deficiency, Cysteine genetics, Dipeptides deficiency, Dipeptides genetics, Ergothioneine deficiency, Ergothioneine genetics, Glycopeptides deficiency, Glycopeptides genetics, Inositol deficiency, Inositol genetics, Mycobacterium tuberculosis chemistry, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis isolation & purification
- Abstract
Mycothiol (MSH) and ergothioneine (ERG) are thiols able to compensate for each other to protect mycobacteria against oxidative stress. Gamma-glutamylcysteine (GGC), another thiol and an intermediate in ERG biosynthesis has detoxification abilities. Five enzymes are involved in ERG biosynthesis, namely EgtA, EgtB, EgtC, EgtD and EgtE. The role of these enzymes in the production of ERG had been unclear. On the other hand, the enzyme MshA is known to be essential for MSH biosynthesis. In this manuscript, we describe the raw data of the generation and characterization of Mycobacterium tuberculosis (M.tb) mutants harbouring a deletion of the gene coding for each of these enzymes, and the raw data of the phenotypic characterization of the obtained thiol-deficient M.tb mutants. High throughput screening (HTS) of off-patent drugs and natural compounds revealed few compounds that displayed a higher activity against the thiol-deficient mutants relative to the wild-type strain. The mode of action of these drugs was further investigated. Raw data displaying these results are described here.
- Published
- 2018
- Full Text
- View/download PDF
5. Dietary myo-inositol deficiency decreased intestinal immune function related to NF-κB and TOR signaling in the intestine of young grass carp (Ctenopharyngodon idella).
- Author
-
Li SA, Jiang WD, Feng L, Liu Y, Wu P, Jiang J, Kuang SY, Tang L, Tang WN, Zhang YA, Yang J, Tang X, Shi HQ, and Zhou XQ
- Subjects
- Animal Feed analysis, Animals, Diet veterinary, Dietary Supplements analysis, NF-kappa B metabolism, TOR Serine-Threonine Kinases metabolism, Carps genetics, Carps immunology, Inositol deficiency, Intestines immunology, Signal Transduction immunology, Vitamin B Complex analysis
- Abstract
In this study, we investigated the effects of dietary myo-inositol on the intestinal immune barrier function and related signaling pathway in young grass carp (Ctenopharyngodon idella). A total of 540 young grass carp (221.33 ± 0.84 g) were fed six diets containing graded levels of myo-inositol (27.0, 137.9, 286.8, 438.6, 587.7 and 737.3 mg/kg) for 10 weeks. After the growth trial, fish were challenged with Aeromonas hydrophila. The results indicated that compared with the optimal dietary myo-inositol level, myo-inositol deficiency (27.0 mg/kg diet): (1) decreased lysozyme (LZ) and acid phosphatase (ACP) activities, as well as complement 3 (C3), C4 and immunoglobulin M (IgM) contents in the proximal intestine (PI), middle intestine (MI) and distal intestine (DI) of young grass carp (P < 0.05). (2) down-regulated the mRNA levels of anti-microbial substance: liver expressed antimicrobial peptide (LEAP) 2A, LEAP-2B, hepcidin, β-defensin-1 and mucin2 in the PI, MI and DI of young grass carp (P < 0.05). (3) up-regulated pro-inflammatory cytokines [IL-1β (not in DI), TNF-α and IL-8], nuclear factor kappa B P65 (not NF-κB P52), c-Rel, IκB kinaseα (IKKα), IKKβ and IKKγ mRNA levels in the PI, MI and DI of young grass carp (P < 0.05); and down-regulated pro-inflammatory cytokines IL-15 (not in DI) and inhibitor of κBα (IκBα) mRNA levels (P < 0.05). (4) down-regulated the mRNA levels of anti-inflammatory cytokines [IL-10 (not in DI), IL-11, IL-4/13B (not IL-4/13A), TGF-β1 and TGF-β2], target of rapamycin (TOR), eIF4E-binding proteins 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6k1) in the PI, MI and DI of young grass carp (P < 0.05). All data indicated that myo-inositol deficiency could decrease fish intestine immunity and cause inflammation under infection of A. hydrophila. Finally, the optimal dietary myo-inositol levels for the ACP and LZ activities in the DI were estimated to be 415.1 and 296.9 mg/kg diet, respectively., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
6. Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders.
- Author
-
Dinicola S, Minini M, Unfer V, Verna R, Cucina A, and Bizzarri M
- Subjects
- Biological Availability, Humans, Inositol pharmacokinetics, Nutritional Status, Inositol deficiency, Metabolic Diseases chemically induced
- Abstract
Communities eating a western-like diet, rich in fat, sugar and significantly deprived of fibers, share a relevant increased risk of both metabolic and cancerous diseases. Even more remarkable is that a low-fiber diet lacks some key components-as phytates and inositols-for which a mechanistic link has been clearly established in the pathogenesis of both cancer and metabolic illness. Reduced bioavailability of inositol in living organisms could arise from reduced food supply or from metabolism deregulation. Inositol deregulation has been found in a number of conditions mechanistically and epidemiologically associated to high-glucose diets or altered glucose metabolism. Indeed, high glucose levels hinder inositol availability by increasing its degradation and by inhibiting both myo-Ins biosynthesis and absorption. These underappreciated mechanisms may likely account for acquired, metabolic deficiency in inositol bioavailability., Competing Interests: The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
7. Dietary myo-inositol deficiency decreased the growth performances and impaired intestinal physical barrier function partly relating to nrf2, jnk, e2f4 and mlck signaling in young grass carp (Ctenopharyngodon idella).
- Author
-
Li SA, Jiang WD, Feng L, Liu Y, Wu P, Jiang J, Kuang SY, Tang L, Tang WN, Zhang YA, Tang X, Shi HQ, and Zhou XQ
- Subjects
- Animal Feed analysis, Animals, Apoptosis drug effects, Carps genetics, Carps growth & development, Cell Proliferation drug effects, Diet veterinary, Dietary Supplements analysis, Intestines drug effects, Random Allocation, Tight Junctions drug effects, Antioxidants metabolism, Carps physiology, Dietary Carbohydrates metabolism, Fish Proteins metabolism, Inositol deficiency, Signal Transduction
- Abstract
In this study, we investigated the effects of dietary myo-inositol on the growth and intestinal physical barrier functions of young grass carp (Ctenopharyngodon idella). A total of 540 young grass carp (221.83 ± 0.84 g) were fed six diets containing graded levels of myo-inositol (27.0, 137.9, 286.8, 438.6, 587.7 and 737.3 mg/kg) for 10 weeks. After the growth trial, fish were challenged with Aeromonas hydrophila for 14 days. The results indicated that compared with optimal myo-inositol levels, myo-inositol deficiency (27.0 mg/kg diet): (1) decreased glutathione (GSH) contents and antioxidant enzymes activities, and down-regulated the mRNA levels of antioxidant enzymes [not glutathione-S-transferase (gst) p1 and gstp2] and NF-E2-related factor 2 (nrf2), whereas up-regulated the reactive oxygen species (ROS), malondialdehyde (MDA) and protein carbonyl (PC) contents, and the mRNA levels of Kelch-like-ECH-associated protein 1 (keap1) in three intestinal segments of young grass carp (P < 0.05). (2) Up-regulated cysteinyl aspartic acid-protease (caspase)-2, -3, -7, -8, -9, apoptotic protease activating factor-1 (apaf-1), Bcl2-associated X protein (bax), fas ligand (fasl), gen-activated protein kinase (p38mapk) and c-Jun N-terminal protein kinase (jnk) mRNA levels, whereas down-regulated B-cell lymphoma-2 (bcl-2), inhibitor of apoptosis proteins (iap) and myeloid cell leukemia-1 (mcl-1) mRNA levels in three intestinal segments of young grass carp (P < 0.05). (3) Down-regulated mRNA levels of cell cycle proteins cyclin b, cyclin d, cyclin e and E2F transcription factor 4 (e2f4) in three intestinal segments of young grass carp (P < 0.05). (4) Down-regulated the mRNA levels of zonula occludens (zo) 1, zo-2, occludin, claudin-b, -c, -f, -3c, -7a, -7b as well as -11, and up-regulated the mRNA levels of claudin-12, -15a (not -15b) and myosin light chain kinase (mlck) in three intestinal segments of young grass carp (P < 0.05). All above data indicated that dietary myo-inositol deficiency could damage physical barrier function in three intestinal segments of fish. Finally, the myo-inositol requirements based on the percent weight gain (PWG), reactive oxygen species (ROS) contents in the proximal intestine (PI), relative mRNA levels of caspase-2 (PI), cyclin b (MI) as well as claudin-b (PI) were estimated to be 276.7, 304.1, 327.9, 416.7 and 313.2 mg/kg diet, respectively., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
8. Inositol and human reproduction. From cellular metabolism to clinical use.
- Author
-
Milewska EM, Czyzyk A, Meczekalski B, and Genazzani AD
- Subjects
- Female, Humans, Inositol deficiency, Inositol metabolism, Inositol therapeutic use, Inositol physiology, Insulin Resistance physiology, Ovulation metabolism, Polycystic Ovary Syndrome metabolism, Reproductive Techniques, Assisted
- Abstract
Inositol is an organic compound of high biological importance that is widely distributed in nature. It belongs to the sugar family and is mainly represented by its two dominant stereoisomers: myo-inositol and D-chiro-inositol that are found in the organism in the physiological serum ratio 40:1. Inositol and its derivatives are important components of the structural phospholipids of the cell membranes and are precursors of the second messengers of many metabolic pathways. A high concentration of myoinositol is found in the follicular fluid and in semen. Inositol deficiency and the impairment of the inositol-dependent pathways may play an important role in the pathogenesis of insulin resistance and hypothyroidism. The results of the research also point out the potential beneficial role of inositol supplementation in polycystic ovarian syndrome and in the context of assisted reproduction technologies and in vitro fertilization. The main aim of the article is to overview the major inositol-dependent metabolic pathways and to discuss its importance for reproduction.
- Published
- 2016
- Full Text
- View/download PDF
9. Quantification of plasma myo-inositol using gas chromatography-mass spectrometry.
- Author
-
Guo J, Shi Y, Xu C, Zhong R, Zhang F, Zhang T, Niu B, and Wang J
- Subjects
- Anencephaly blood, Anencephaly diagnosis, Female, Humans, Inositol deficiency, Male, Mass Screening methods, Neural Tube Defects diagnosis, Pregnancy, Prenatal Diagnosis, Reference Standards, Sensitivity and Specificity, Spinal Dysraphism diagnosis, Gas Chromatography-Mass Spectrometry methods, Inositol blood
- Abstract
Background: Myo-inositol (MI) deficiency is associated with an increased risk for neural tube defects (NTDs), mental disorders and metabolic diseases. We developed a gas chromatography-mass spectrometry (GC-MS) method to detect MI in human plasma, which was accurate, relatively efficient and convenient for clinical application., Methods: An external standard method was used for determination of plasma MI. Samples were analyzed by GC-MS after derivatization. The stable-isotope labeled internal standard approach was used to validate the method's accuracy. Alpha fetal protein (AFP) was detected by chemiluminescence immunoassay., Results: The method was validated by determining the linearity, sensitivity and recovery rate. There was a good agreement between the internal standard approach and the present method. The NTD-affected pregnancies showed lower plasma MI (P=0.024) and higher AFP levels (P=0.001) than control. Maternal MI level showed a better discrimination in spina bifida subgroup, while AFP level showed a better discrimination in anencephaly subgroup after stratification analysis., Conclusions: We developed a sensitive and reliable method for the detection of clinical plasma MI, which might be a marker for NTDs screening, and established fundamental knowledge for clinical diagnosis and prevention for the diseases related to disturbed MI metabolism., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. Perturbation of the Vacuolar ATPase: A NOVEL CONSEQUENCE OF INOSITOL DEPLETION.
- Author
-
Deranieh RM, Shi Y, Tarsio M, Chen Y, McCaffery JM, Kane PM, and Greenberg ML
- Subjects
- Drug Resistance, Fungal genetics, Gene Deletion, Homeostasis, Inositol genetics, Myo-Inositol-1-Phosphate Synthase genetics, Osmotic Pressure, Phosphatidylinositol Phosphates metabolism, Protein Transport, Saccharomyces cerevisiae drug effects, Saccharomyces cerevisiae enzymology, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae Proteins genetics, Vacuolar Proton-Translocating ATPases genetics, Anticonvulsants pharmacology, Inositol deficiency, Intramolecular Lyases antagonists & inhibitors, Vacuolar Proton-Translocating ATPases metabolism, Vacuoles enzymology, Valproic Acid pharmacology
- Abstract
Depletion of inositol has profound effects on cell function and has been implicated in the therapeutic effects of drugs used to treat epilepsy and bipolar disorder. We have previously shown that the anticonvulsant drug valproate (VPA) depletes inositol by inhibiting myo-inositol-3-phosphate synthase, the enzyme that catalyzes the first and rate-limiting step of inositol biosynthesis. To elucidate the cellular consequences of inositol depletion, we screened the yeast deletion collection for VPA-sensitive mutants and identified mutants in vacuolar sorting and the vacuolar ATPase (V-ATPase). Inositol depletion caused by starvation of ino1Δ cells perturbed the vacuolar structure and decreased V-ATPase activity and proton pumping in isolated vacuolar vesicles. VPA compromised the dynamics of phosphatidylinositol 3,5-bisphosphate (PI3,5P2) and greatly reduced V-ATPase proton transport in inositol-deprived wild-type cells. Osmotic stress, known to increase PI3,5P2 levels, did not restore PI3,5P2 homeostasis nor did it induce vacuolar fragmentation in VPA-treated cells, suggesting that perturbation of the V-ATPase is a consequence of altered PI3,5P2 homeostasis under inositol-limiting conditions. This study is the first to demonstrate that inositol depletion caused by starvation of an inositol synthesis mutant or by the inositol-depleting drug VPA leads to perturbation of the V-ATPase., (© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
11. Renal depletion of myo-inositol is associated with its increased degradation in animal models of metabolic disease.
- Author
-
Chang HH, Chao HN, Walker CS, Choong SY, Phillips A, and Loomes KM
- Subjects
- Animals, Diabetes Mellitus, Experimental complications, Diabetes Mellitus, Experimental genetics, Diabetic Nephropathies etiology, Diabetic Nephropathies metabolism, Hypertension complications, Hypertension genetics, Inositol deficiency, Inositol Oxygenase genetics, Inositol Oxygenase metabolism, Insulin Resistance, Kidney Tubules, Proximal enzymology, Male, Mice, Inbred C57BL, Obesity complications, Obesity genetics, Proteins genetics, Proteins metabolism, Rats, Inbred SHR, Rats, Inbred WKY, Rats, Wistar, Xylulose genetics, Xylulose metabolism, Diabetes Mellitus, Experimental metabolism, Hypertension metabolism, Inositol metabolism, Kidney Tubules, Proximal metabolism, Obesity metabolism
- Abstract
Renal depletion of myo-inositol (MI) is associated with the pathogenesis of diabetic nephropathy in animal models, but the underlying mechanisms involved are unclear. We hypothesized that MI depletion was due to changes in inositol metabolism and therefore examined the expression of genes regulating de novo biosynthesis, reabsorption, and catabolism of MI. We also extended the analyses from diabetes mellitus to animal models of dietary-induced obesity and hypertension. We found that renal MI depletion was pervasive across these three distinct disease states in the relative order: hypertension (-51%)>diabetes mellitus (-35%)>dietary-induced obesity (-19%). In 4-wk diabetic kidneys and in kidneys derived from insulin-resistant and hypertensive rats, MI depletion was correlated with activity of the MI-degrading enzyme myo-inositol oxygenase (MIOX). By contrast, there was decreased MIOX expression in 8-wk diabetic kidneys. Immunohistochemistry localized the MI-degrading pathway comprising MIOX and the glucuronate-xylulose (GX) pathway to the proximal tubules within the renal cortex. These findings indicate that MI depletion could reflect increased catabolism through MIOX and the GX pathway and implicate a common pathological mechanism contributing to renal oxidative stress in metabolic disease., (Copyright © 2015 the American Physiological Society.)
- Published
- 2015
- Full Text
- View/download PDF
12. Ergothioneine protects Streptomyces coelicolor A3(2) from oxidative stresses.
- Author
-
Nakajima S, Satoh Y, Yanashima K, Matsui T, and Dairi T
- Subjects
- Cysteine analogs & derivatives, Cysteine biosynthesis, Cysteine deficiency, Cysteine metabolism, Ergothioneine biosynthesis, Ergothioneine deficiency, Glutamate-Cysteine Ligase deficiency, Glutamate-Cysteine Ligase genetics, Glutamate-Cysteine Ligase metabolism, Glycopeptides biosynthesis, Glycopeptides deficiency, Glycopeptides metabolism, Hydrogen Peroxide chemistry, Hydrogen Peroxide pharmacology, Inositol biosynthesis, Inositol deficiency, Inositol metabolism, Streptomyces coelicolor drug effects, Streptomyces coelicolor enzymology, Streptomyces coelicolor genetics, Ergothioneine metabolism, Oxidative Stress drug effects, Streptomyces coelicolor metabolism
- Abstract
Thiol compounds with low-molecular weight, such as glutathione, mycothiol (MSH), bacillithiol, and ergothioneine (ERG), are known to protect microorganisms from oxidative stresses. Mycobacteria and actinobacteria utilize both MSH and ERG. The biological functions of MSH in mycobacteria have been extensively studied by genetic and biochemical studies, which have suggested it has critical roles for detoxification in cells. In contrast, the biological functions of ERG remain ambiguous because its biosynthetic genes were only recently identified in Mycobacterium avium. In this study, we constructed mutants of Streptomyces coelicolor A3(2), in which either the MSH or ERG biosynthetic gene was disrupted, and examined their phenotypes. A mshC (SCO1663)-disruptant completely lost MSH productivity. In contrast, a disruptant of the egtA gene (SCO0910) encoding γ-glutamyl-cysteine synthetase unexpectedly retained reduced productivity of ERG, probably because of the use of l-cysteine instead of γ-glutamyl-cysteine. Both disruptants showed delayed growth at the late logarithmic phase and were more susceptible to hydrogen peroxide and cumene hydroperoxide than the parental strain. Interestingly, the ERG-disruptant, which still kept reduced ERG productivity, was more susceptible. Furthermore, the ERG-disruptant accumulated 5-fold more MSH than the parental strain. In contrast, the amount of ERG was almost the same between the MSH-disruptant and the parental strain. Taken together, our results suggest that ERG is more important than MSH in S. coelicolor A3(2)., (Copyright © 2015 The Society for Biotechnology, Japan. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
13. Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation.
- Author
-
Croze ML, Géloën A, and Soulage CO
- Subjects
- Adipokines blood, Adipose Tissue, White enzymology, Adipose Tissue, White metabolism, Animals, Dietary Supplements, Fatty Acid Synthases metabolism, Hyperglycemia metabolism, Inositol analysis, Inositol deficiency, Inositol urine, Insulin Resistance, Kidney chemistry, Lipid Metabolism drug effects, Liver chemistry, Male, Mice, Mice, Inbred C57BL, Obesity etiology, Obesity metabolism, Obesity prevention & control, Diabetes Mellitus, Type 2 metabolism, Diet, High-Fat, Inositol administration & dosage, Inositol metabolism
- Abstract
We previously reported that a chronic supplementation with myo-inositol (MI) improved insulin sensitivity and reduced fat accretion in mice. We then tested the potency of such dietary intervention in the prevention of insulin resistance in C57BL/6 male mouse fed a high-fat diet (HFD). In addition, some abnormalities in inositol metabolism were reported to be associated with insulin resistance in several animal and human studies. We then investigated the presence of such anomalies (i.e. inosituria and an inositol intra-tissue depletion) in this diet-induced obesity (DIO) mouse model, as well as the potential benefit of a MI supplementation for inositol intra-tissue deficiency correction. HFD (60 % energy from fat) feeding was associated with inosituria and inositol intra-tissue depletion in the liver and kidneys. MI supplementation (0·58 mg/g per d) restored inositol pools in kidneys (partially) and liver (fully). HFD feeding for 4 months induced ectopic lipid redistribution to liver and muscles, fasting hyperglycaemia and hyperinsulinaemia, insulin resistance and obesity that were not prevented by MI supplementation, despite a significant improvement in insulin sensitivity parameter K insulin tolerance test and a reduction in white adipose tissue (WAT) mass ( - 17 %, P< 0·05). MI supplementation significantly reduced fatty acid synthase activity in epididymal WAT, which might explain its beneficial, but modest, effect on WAT accretion in HFD-fed mice. Finally, we found some abnormalities in inositol metabolism in association with a diabetic phenotype (i.e. insulin resistance and fasting hyperglycaemia) in a DIO mouse model. Dietary MI supplementation was efficient in the prevention of inositol intra-tissue depletion, but did not prevent insulin resistance or obesity efficiently in this mouse model.
- Published
- 2015
- Full Text
- View/download PDF
14. Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder.
- Author
-
Shtein L, Agam G, Belmaker RH, and Bersudsky Y
- Subjects
- Animals, Behavior, Animal drug effects, Bipolar Disorder psychology, Diet, Enzyme Inhibitors pharmacology, Mice, Mice, Inbred ICR, Pilocarpine, Antimanic Agents therapeutic use, Behavior drug effects, Bipolar Disorder drug therapy, Inositol deficiency, Lithium Compounds therapeutic use, Phosphoric Monoester Hydrolases antagonists & inhibitors, Vitamin B Deficiency psychology
- Abstract
Lithium treatment in rodents markedly enhances cholinergic agonists such as pilocarpine. This effect can be reversed in a stereospecific manner by administration of inositol, suggesting that the effect of lithium is caused by inositol monophosphatase inhibition and consequent inositol depletion. If so, inositol-deficient food would be expected to enhance lithium effects. Inositol-deficient food was prepared from inositol-free ingredients. Mice with a homozygote knockout of the inositol monophosphatase 1 gene unable to synthesize inositol endogenously and mimicking lithium-treated animals were fed this diet or a control diet. Lithium-treated wild-type animals were also treated with the inositol-deficient diet or control diet. Pilocarpine was administered after 1 week of treatment, and behavior including seizures was assessed using rating scale. Inositol-deficient food-treated animals, both lithium treated and with inositol monophosphatase 1 knockout, had significantly elevated cholinergic behavior rating and significantly increased or earlier seizures compared with the controls. The effect of inositol-deficient food supports the role of inositol depletion in the effects of lithium on pilocarpine-induced behavior. However, the relevance of this behavior to other more mood-related effects of lithium is not clear.
- Published
- 2015
- Full Text
- View/download PDF
15. Inositol depletion restores vesicle transport in yeast phospholipid flippase mutants.
- Author
-
Yamagami K, Yamamoto T, Sakai S, Mioka T, Sano T, Igarashi Y, and Tanaka K
- Subjects
- Carrier Proteins genetics, Carrier Proteins metabolism, Endocytosis, Endosomes metabolism, Inositol deficiency, Monosaccharide Transport Proteins genetics, Monosaccharide Transport Proteins metabolism, Phosphatidylinositols metabolism, Phosphatidylserines metabolism, Phospholipid Transfer Proteins genetics, Protein Transport, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae Proteins genetics, Saccharomyces cerevisiae Proteins metabolism, Transferases (Other Substituted Phosphate Groups) genetics, Transferases (Other Substituted Phosphate Groups) metabolism, Inositol metabolism, Phospholipid Transfer Proteins metabolism, Saccharomyces cerevisiae metabolism
- Abstract
In eukaryotic cells, type 4 P-type ATPases function as phospholipid flippases, which translocate phospholipids from the exoplasmic leaflet to the cytoplasmic leaflet of the lipid bilayer. Flippases function in the formation of transport vesicles, but the mechanism remains unknown. Here, we isolate an arrestin-related trafficking adaptor, ART5, as a multicopy suppressor of the growth and endocytic recycling defects of flippase mutants in budding yeast. Consistent with a previous report that Art5p downregulates the inositol transporter Itr1p by endocytosis, we found that flippase mutations were also suppressed by the disruption of ITR1, as well as by depletion of inositol from the culture medium. Interestingly, inositol depletion suppressed the defects in all five flippase mutants. Inositol depletion also partially restored the formation of secretory vesicles in a flippase mutant. Inositol depletion caused changes in lipid composition, including a decrease in phosphatidylinositol and an increase in phosphatidylserine. A reduction in phosphatidylinositol levels caused by partially depleting the phosphatidylinositol synthase Pis1p also suppressed a flippase mutation. These results suggest that inositol depletion changes the lipid composition of the endosomal/TGN membranes, which results in vesicle formation from these membranes in the absence of flippases.
- Published
- 2015
- Full Text
- View/download PDF
16. Inositol-related gene knockouts mimic lithium's effect on mitochondrial function.
- Author
-
Toker L, Bersudsky Y, Plaschkes I, Chalifa-Caspi V, Berry GT, Buccafusca R, Moechars D, Belmaker RH, and Agam G
- Subjects
- Animals, Male, Mice, Mice, 129 Strain, Mice, Inbred C57BL, Mice, Knockout, Mitochondria genetics, Gene Knockout Techniques methods, Inositol deficiency, Inositol genetics, Lithium pharmacology, Mitochondria drug effects, Mitochondria physiology
- Abstract
The inositol-depletion hypothesis proposes that lithium attenuates phosphatidylinositol signaling. Knockout (KO) mice of two genes (IMPA1 or Slc5a3), each encoding for a protein related to inositol metabolism, were studied in comparison with lithium-treated mice. Since we previously demonstrated that these KO mice exhibit a lithium-like neurochemical and behavioral phenotype, here we searched for pathways that may mediate lithium's/the KO effects. We performed a DNA-microarray study searching for pathways affected both by chronic lithium treatment and by the KO of each of the genes. The data were analyzed using three different bioinformatics approaches. We found upregulation of mitochondria-related genes in frontal cortex of lithium-treated, IMPA1 and Slc5a3 KO mice. Three out of seven genes differentially expressed in all three models, Cox5a, Ndufs7, and Ndufab, all members of the mitochondrial electron transfer chain, have previously been associated with bipolar disorder and/or lithium treatment. Upregulation of the expression of these genes was verified by real-time PCR. To further support the link between mitochondrial function and lithium's effect on behavior, we determined the capacity of chronic low-dose rotenone, a mitochondrial respiratory chain complex I inhibitor, to alter lithium-induced behavior as measured by the forced-swim and the amphetamine-induced hyperlocomotion paradigms. Rontenone treatment counteracted lithium's effect on behavior, supporting the proposition suggested by the bioinformatics analysis for a mitochondrial function involvement in behavioral effects of lithium mediated by inositol metabolism alterations.The results provide support for the notion that mitochondrial dysfunction is linked to bipolar disorder and can be ameliorated by lithium. The phenotypic similarities between lithium-treated wild-type mice and the two KO models suggest that lithium may affect behavior by altering inositol metabolism.
- Published
- 2014
- Full Text
- View/download PDF
17. [The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders].
- Author
-
Jakimiuk AJ and Szamatowicz J
- Subjects
- Blood Glucose drug effects, Female, Folic Acid therapeutic use, Follicular Phase drug effects, Humans, Polycystic Ovary Syndrome etiology, Polycystic Ovary Syndrome prevention & control, Randomized Controlled Trials as Topic, Women's Health, Inositol deficiency, Inositol therapeutic use, Ovary drug effects, Polycystic Ovary Syndrome drug therapy, Polycystic Ovary Syndrome metabolism, Vitamin B Complex therapeutic use
- Abstract
Inositol acts as a second messenger in insulin signaling pathway Literature data suggest inositol deficiency in insulin-resistant women with the polycystic ovary syndrome. Supplementation of myo-inisitol decreases insulin resistance as it works as an insulin sensitizing agent. The positive role of myo-inositol in the treatment of polycystic ovary syndrome has been of increased evidence recently The present review presents the effects of myo-inositol on the ovarian, hormonal and metabolic parameters in women with PCOS.
- Published
- 2014
- Full Text
- View/download PDF
18. Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica.
- Author
-
Ciccarelli O, Thomas DL, De Vita E, Wheeler-Kingshott CA, Kachramanoglou C, Kapoor R, Leary S, Matthews L, Palace J, Chard D, Miller DH, Toosy AT, and Thompson AJ
- Subjects
- Adult, Astrocytes metabolism, Biomarkers, Cervical Vertebrae pathology, Diagnosis, Differential, Female, Humans, Inositol deficiency, Male, Middle Aged, Multiple Sclerosis diagnosis, Multiple Sclerosis metabolism, Multiple Sclerosis pathology, Neuromyelitis Optica diagnosis, Neuromyelitis Optica metabolism, Spinal Cord metabolism, Astrocytes pathology, Inositol metabolism, Neuromyelitis Optica pathology, Spinal Cord pathology
- Abstract
Astrocytic necrosis is a prominent pathological feature of neuromyelitis optica (NMO) lesions and is clinically relevant. We report 5 NMO-related cases, all with longitudinally extensive lesions in the upper cervical cord, who underwent cervical cord (1) H-magnetic resonance spectroscopy. Lower myo-inositol/creatine values, suggesting astrocytic damage, were consistently found within the NMO lesions when compared with healthy controls and patients with multiple sclerosis (MS), who showed at least 1 demyelinating lesion at the same cord level. Therefore, the in vivo quantification of myo-inositol may distinguish NMO from MS. This is an important step toward developing imaging markers for clinical trials in NMO., (© 2013 American Neurological Association.)
- Published
- 2013
- Full Text
- View/download PDF
19. BiP-bound and nonclustered mode of Ire1 evokes a weak but sustained unfolded protein response.
- Author
-
Ishiwata-Kimata Y, Promlek T, Kohno K, and Kimata Y
- Subjects
- Endoplasmic Reticulum metabolism, Endoplasmic Reticulum Stress, Fungal Proteins genetics, HSP70 Heat-Shock Proteins genetics, Inositol deficiency, Membrane Glycoproteins chemistry, Membrane Glycoproteins genetics, Mutation, Missense, Protein Binding, Protein Multimerization, Protein Serine-Threonine Kinases chemistry, Protein Serine-Threonine Kinases genetics, Protein Unfolding, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae Proteins chemistry, Saccharomyces cerevisiae Proteins genetics, Fungal Proteins metabolism, HSP70 Heat-Shock Proteins metabolism, Membrane Glycoproteins metabolism, Protein Serine-Threonine Kinases metabolism, Saccharomyces cerevisiae Proteins metabolism, Unfolded Protein Response
- Abstract
In eukaryotic cells under nonstressed conditions, the endoplasmic reticulum (ER)-located molecular chaperone BiP is associated with an ER-membrane protein Ire1 to inhibit its self-association. While ER stress leads Ire1 to form transiently BiP-unbound clusters, which strongly evoke the unfolded protein response (UPR), here we propose an alternative activation status of Ire1. When yeast cells are physiologically ER-stressed by inositol depletion for a prolonged time, the UPR is weakly activated in a sustained manner after a transient peak of activation. During persistent stress, Ire1 foci disappear, while Ire1 continues to be self-associated. Under these conditions, Ire1 may be activated as a homo-dimer, as it shows considerable activity even when carrying the W426A mutation, which allows Ire1 to form homo-dimers but not clusters. Unlike the Ire1 clusters, the nonclustered active form seems to be associated with BiP. An Ire1 mutant not carrying the BiP-association site continued to form clusters and to be activated strongly even after long-term stress. Similar observations were obtained when cells were ER-stressed by dithiothreitol. We thus propose that upon persistent ER stress, Ire1 is weakly and continuously activated in a nonclustered form through its (re)association with BiP, which disperses the Ire1 clusters., (© 2013 The Authors Genes to Cells © 2013 by the Molecular Biology Society of Japan and Wiley Publishing Asia Pty Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
20. A safe lithium mimetic for bipolar disorder.
- Author
-
Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon EC, Aley PK, Antoniadou I, Sharp T, Vasudevan SR, and Churchill GC
- Subjects
- Animals, Azoles chemistry, Azoles pharmacology, Azoles therapeutic use, Behavior, Animal drug effects, Bipolar Disorder enzymology, Bipolar Disorder pathology, Blood-Brain Barrier drug effects, Blood-Brain Barrier enzymology, Blood-Brain Barrier pathology, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Humans, Inositol deficiency, Inositol pharmacology, Isoindoles, Lithium pharmacology, Male, Mice, Mice, Inbred C57BL, Organoselenium Compounds chemistry, Organoselenium Compounds pharmacology, Organoselenium Compounds therapeutic use, Phosphoric Monoester Hydrolases antagonists & inhibitors, Phosphoric Monoester Hydrolases metabolism, Bipolar Disorder drug therapy, Lithium therapeutic use, Molecular Mimicry
- Abstract
Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects. It is likely that a small molecule could be found with lithium-like efficacy but without toxicity through target-based drug discovery; however, therapeutic target of lithium remains equivocal. Inositol monophosphatase is a possible target but no bioavailable inhibitors exist. Here we report that the antioxidant ebselen inhibits inositol monophosphatase and induces lithium-like effects on mouse behaviour, which are reversed with inositol, consistent with a mechanism involving inhibition of inositol recycling. Ebselen is part of the National Institutes of Health Clinical Collection, a chemical library of bioavailable drugs considered clinically safe but without proven use. Therefore, ebselen represents a lithium mimetic with the potential both to validate inositol monophosphatase inhibition as a treatment for bipolar disorder and to serve as a treatment itself.
- Published
- 2013
- Full Text
- View/download PDF
21. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction.
- Author
-
Vilchèze C, Hartman T, Weinrick B, and Jacobs WR Jr
- Subjects
- Antitubercular Agents pharmacology, Cysteine deficiency, DNA Damage, Drug Resistance, Bacterial drug effects, Glycopeptides deficiency, Inositol deficiency, Lipids biosynthesis, Microbial Sensitivity Tests, Models, Biological, Mycobacterium tuberculosis genetics, Oxidants pharmacology, Reactive Oxygen Species metabolism, Sterilization, Transcription, Genetic drug effects, Ascorbic Acid pharmacology, Hydrogen Peroxide metabolism, Iron metabolism, Microbial Viability drug effects, Mycobacterium tuberculosis drug effects
- Abstract
Drugs that kill tuberculosis more quickly could shorten chemotherapy significantly. In Escherichia coli, a common mechanism of cell death by bactericidal antibiotics involves the generation of highly reactive hydroxyl radicals via the Fenton reaction. Here we show that vitamin C, a compound known to drive the Fenton reaction, sterilizes cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis. While M. tuberculosis is highly susceptible to killing by vitamin C, other Gram-positive and Gram-negative pathogens are not. The bactericidal activity of vitamin C against M. tuberculosis is dependent on high ferrous ion levels and reactive oxygen species production, and causes a pleiotropic effect affecting several biological processes. This study enlightens the possible benefits of adding vitamin C to an anti-tuberculosis regimen and suggests that the development of drugs that generate high oxidative burst could be of great use in tuberculosis treatment.
- Published
- 2013
- Full Text
- View/download PDF
22. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
- Author
-
Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, and Artini PG
- Subjects
- Adult, Body Mass Index, Female, Folic Acid therapeutic use, Follicle Stimulating Hormone blood, Glucose Tolerance Test, Humans, Hyperinsulinism etiology, Inositol deficiency, Inositol Phosphates metabolism, Insulin blood, Insulin Antagonists metabolism, Luteinizing Hormone blood, Polycystic Ovary Syndrome complications, Polycystic Ovary Syndrome metabolism, Polycystic Ovary Syndrome physiopathology, Polysaccharides metabolism, Weight Loss, Dietary Supplements, Hyperinsulinism prevention & control, Inositol therapeutic use, Insulin Resistance, Obesity complications, Overweight complications, Polycystic Ovary Syndrome diet therapy
- Abstract
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, polycystic ovaries at ultrasound evaluation, and quite frequently by insulin resistance or compensatory hyperinsulinemia. Attention has been given to the role of inositol-phosphoglycan (IPG) mediators of insulin action and growing evidences suggest that a deficiency of D-chiro-inositol (DCI) containing IPG might be at the basis of insulin resistance, frequent in PCOS patients. On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,. After the treatment interval body mass index (BMI) and insulin resistance decreased together with luteinizing hormone (LH), LH/FSH and insulin. When subdividing the patients according to their fasting insulin levels, Group A (n = 15) insulin below 12 µU/ml and Group B (n = 27) insulin above 12 µU/ml, MYO treatment induced similar changes in both groups but only patients of Group B showed the significant decrease of both fasting insulin plasma levels (from 20.3 ± 1.8 to 12.9 ± 1.8 µU/ml, p < 0.00001) and of area under the curve (AUC) of insulin under oral glucose tolerance test (OGTT). In conclusion, our study supports the hypothesis that MYO administration is more effective in obese patients with high fasting insulin plasma levels.
- Published
- 2012
- Full Text
- View/download PDF
23. Membrane aberrancy and unfolded proteins activate the endoplasmic reticulum stress sensor Ire1 in different ways.
- Author
-
Promlek T, Ishiwata-Kimata Y, Shido M, Sakuramoto M, Kohno K, and Kimata Y
- Subjects
- Amino Acid Substitution, Basic-Leucine Zipper Transcription Factors genetics, Basic-Leucine Zipper Transcription Factors metabolism, Carboxypeptidases genetics, Carboxypeptidases metabolism, Gene Deletion, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, Immunoprecipitation, Inositol deficiency, Mutagenesis, Site-Directed, Protein Binding, RNA Splicing, RNA, Messenger metabolism, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Repressor Proteins genetics, Repressor Proteins metabolism, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae Proteins genetics, Cell Membrane metabolism, Endoplasmic Reticulum Stress, Enzyme Activation, Membrane Glycoproteins metabolism, Protein Serine-Threonine Kinases metabolism, Saccharomyces cerevisiae physiology, Saccharomyces cerevisiae Proteins metabolism, Unfolded Protein Response
- Abstract
Eukaryotic cells activate the unfolded-protein response (UPR) upon endoplasmic reticulum (ER) stress, where the stress is assumed to be the accumulation of unfolded proteins in the ER. Consistent with previous in vitro studies of the ER-luminal domain of the mutant UPR initiator Ire1, our study show its association with a model unfolded protein in yeast cells. An Ire1 luminal domain mutation that compromises Ire1's unfolded-protein-associating ability weakens its ability to respond to stress stimuli, likely resulting in the accumulation of unfolded proteins in the ER. In contrast, this mutant was activated like wild-type Ire1 by depletion of the membrane lipid component inositol or by deletion of genes involved in lipid homeostasis. Another Ire1 mutant lacking the authentic luminal domain was up-regulated by inositol depletion as strongly as wild-type Ire1. We therefore conclude that the cytosolic (or transmembrane) domain of Ire1 senses membrane aberrancy, while, as proposed previously, unfolded proteins accumulating in the ER interact with and activate Ire1.
- Published
- 2011
- Full Text
- View/download PDF
24. Polycystic ovary syndrome: a vitamin deficiency? Floating a new pathogenesis hypothesis.
- Author
-
Unfer V
- Subjects
- Dietary Supplements, Female, Humans, Inositol administration & dosage, Polycystic Ovary Syndrome drug therapy, Polycystic Ovary Syndrome metabolism, Risk Factors, Treatment Outcome, Vitamin B Complex administration & dosage, Vitamin B Deficiency drug therapy, Vitamin B Deficiency metabolism, Inositol deficiency, Polycystic Ovary Syndrome etiology, Vitamin B Deficiency complications
- Published
- 2010
25. Yeast bioassay for identification of inositol depleting compounds.
- Author
-
Ding D, Shi Y, Shaltiel G, Azab AN, Pullumbi E, Campbell A, Mehta DV, Agam G, and Greenberg ML
- Subjects
- Biological Assay, Cell Proliferation drug effects, Chronic Disease, Humans, Intracellular Space drug effects, Intracellular Space metabolism, Myo-Inositol-1-Phosphate Synthase drug effects, Myo-Inositol-1-Phosphate Synthase genetics, Saccharomyces cerevisiae Proteins drug effects, Saccharomyces cerevisiae Proteins genetics, Anticonvulsants adverse effects, Antimanic Agents adverse effects, Bipolar Disorder drug therapy, Brain drug effects, Brain metabolism, Carboxylic Acids adverse effects, Inositol deficiency, Inositol metabolism, Lithium Carbonate adverse effects, Valproic Acid adverse effects, Yeasts physiology
- Abstract
Bipolar affective disorder is a chronic, severe, debilitating illness affecting 1-2% of the population. Valproate, along with lithium and carbamazepine, are the only drugs for which long-term efficacy has been established. However, these drugs are ineffective for, and not well tolerated by, a large number of patients and are also associated with teratogenicity and reproductive defects. Therefore, there is a substantial need to develop more effective anti-bipolar drugs. We have previously shown that valproate, like lithium, decreases intracellular inositol, which supports the inositol depletion hypothesis. We employed inositol depletion in yeast as a screening tool to identify potential new anti-bipolar medications. We show here that hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, ethylhexanoate, and methyloctanoate decrease intracellular inositol levels and increase the expression of INO1, the gene encoding myo-inositol-3-phosphate synthase (MIPS). Similar to valproate, these inositol-depleting carboxylic acids inhibited MIPS indirectly. A correlation was shown between cell growth inhibition and the increase in INO1 expression by the carboxylic acids, factors that were reversed in the presence of inositol. Inositol depletion in yeast may be exploited as an easy and inexpensive screening test for potential new inositol depleting anti-bipolar drugs.
- Published
- 2009
- Full Text
- View/download PDF
26. IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity.
- Author
-
Cryns K, Shamir A, Van Acker N, Levi I, Daneels G, Goris I, Bouwknecht JA, Andries L, Kass S, Agam G, Belmaker H, Bersudsky Y, Steckler T, and Moechars D
- Subjects
- Animals, Behavior, Animal drug effects, Body Weight drug effects, Chromatography, Gas, Drinking drug effects, Inositol deficiency, Inositol pharmacology, Male, Mice, Mice, Knockout, Motor Activity drug effects, Mutagenesis, Phosphoric Monoester Hydrolases metabolism, Reverse Transcriptase Polymerase Chain Reaction, Swimming psychology, Antimanic Agents pharmacology, Embryonic Development genetics, Lithium Carbonate pharmacology, Muscarinic Agonists pharmacology, Phosphoric Monoester Hydrolases genetics, Pilocarpine pharmacology
- Abstract
Lithium has been the standard pharmacological treatment for bipolar disorder over the last 50 years; however, the molecular targets through which lithium exerts its therapeutic effects are still not defined. We characterized the phenotype of mice with a dysfunctional IMPA1 gene (IMPA1-/-) to study the in vivo physiological functions of IMPA1, in general, and more specifically its potential role as a molecular target in mediating lithium-dependent physiological effects. Homozygote IMPA1-/- mice died in utero between days 9.5 and 10.5 post coitum (p.c.) demonstrating the importance of IMPA1 in early embryonic development. Intriguingly, the embryonic lethality could be reversed by myo-inositol supplementation via the pregnant mothers. In brains of adult IMPA1-/- mice, IMPase activity levels were found to be reduced (up to 65% in hippocampus); however, inositol levels were not found to be altered. Behavioral analysis of the IMPA1-/- mice indicated an increased motor activity in both the open-field test and the forced-swim test as well as a strongly increased sensitivity to pilocarpine-induced seizures, the latter supporting the idea that IMPA1 represents a physiologically relevant target for lithium. In conclusion the IMPA1-/- mouse represents a novel model to study inositol homeostasis, and indicates that genetic inactivation of IMPA1 can mimic some actions of lithium.
- Published
- 2008
- Full Text
- View/download PDF
27. Specificity of mood stabilizer action on neuronal growth cones.
- Author
-
Shaltiel G, Dalton EC, Belmaker RH, Harwood AJ, and Agam G
- Subjects
- Animals, Animals, Newborn, Inositol antagonists & inhibitors, Inositol deficiency, Lithium Compounds administration & dosage, Lithium Compounds adverse effects, Rats, Rats, Sprague-Dawley, Sensitivity and Specificity, Spinal Cord metabolism, Valproic Acid administration & dosage, Valproic Acid adverse effects, Ganglia, Spinal cytology, Ganglia, Spinal drug effects, Ganglia, Spinal growth & development, Psychotropic Drugs adverse effects, Spinal Cord cytology, Spinal Cord drug effects
- Abstract
Objectives: Lithium, valproic acid (VPA) and carbamazepine (CBZ) are commonly used mood stabilizers, but their therapeutic mechanism is unclear. These drugs all cause the same morphological effects on postnatal rat neuronal dorsal root ganglia (DRG) growth cones via an inositol-reversible mechanism. However, due to limitations in earlier analysis, the effects of combining drugs, drug specificity and inositol stereoisomer specificity are unknown. We devised an improved analytical method to address these issues., Methods: Dorsal root ganglia explants were cultured individually and incubated with combinations of psychotropic drugs and inositol stereoisomers. We recorded axonal growth cone morphology and calculated growth cone area per a modified method described by Williams et al. (Nature 2002; 417: 292-295). Statistically significant changes in area were calculated using non-parametric statistical testing., Results: (i) Lithium and VPA showed an additive effect on growth cone spreading. (ii) Among eight additional psychotropic drugs to those previously tested, only imipramine and chlorpromazine altered DRG growth cone morphology. As this effect was not reversed by myo-inositol, it arises from a different mechanism to the mood stabilizers lithium, VPA and CBZ. (iii) Myo-inositol, but not scyllo- or epi-inositol, causes a significant reversal of the lithium effect on the growth cones spreading, consistent with the inositol depletion hypothesis., Conclusions: These results show that lithium, VPA and CBZ are unique in causing altered neuronal morphology via myo-inositol depletion.
- Published
- 2007
- Full Text
- View/download PDF
28. Behavioural phenotyping of sodium-myo-inositol cotransporter heterozygous knockout mice with reduced brain inositol.
- Author
-
Shaldubina A, Buccafusca R, Johanson RA, Agam G, Belmaker RH, Berry GT, and Bersudsky Y
- Subjects
- Analysis of Variance, Animals, Female, Heterozygote, Inositol deficiency, Intracellular Fluid metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Models, Animal, Phenotype, Symporters genetics, Behavior, Animal physiology, Frontal Lobe metabolism, Hippocampus metabolism, Inositol metabolism, Symporters physiology
- Abstract
Inositol plays a key role in dopamine, serotonin, noradrenaline and acetylcholine neurotransmission, and inositol treatment is reported to have beneficial effects in depression and anxiety. Therefore, a reduction in brain intracellular inositol levels could be a cause of some psychiatric disorders, such as depression or anxiety. To determine the behavioural consequences of inositol depletion, we studied the behaviour of sodium-dependent myo-inositol cotransporter-1 heterozygous knockout mice. In heterozygous mice, free inositol levels were reduced by 15% in the frontal cortex and by 25% in the hippocampus, but they did not differ from their wild-type littermates in cholinergic-mediated lithium-pilocarpine seizures, in the apomorphine-induced stereotypic climbing model of dopaminergic system function, in the Porsolt forced-swimming test model of depression, in amphetamine-induced hyperactivity, or in the elevated plus-maze model of anxiety. Reduction of brain inositol by more than 25% may be required to elicit neurobehavioural effects.
- Published
- 2007
- Full Text
- View/download PDF
29. Lithium-pilocarpine seizures as a model for lithium action in mania.
- Author
-
Belmaker RH and Bersudsky Y
- Subjects
- Animals, Antimanic Agents therapeutic use, Bipolar Disorder drug therapy, Bipolar Disorder physiopathology, Disease Models, Animal, Humans, Inositol metabolism, Limbic System drug effects, Limbic System metabolism, Lithium Compounds adverse effects, Lithium Compounds therapeutic use, Mice, Mice, Knockout, Pilocarpine, Rats, Seizures metabolism, Bipolar Disorder metabolism, Inositol deficiency, Lithium Compounds pharmacology, Seizures chemically induced
- Abstract
Lithium (Li) pre-treatment of rats or mice given low dose pilocarpine induces a unique limbic seizure syndrome. This syndrome is stereospecifically reversed by myo-inositol, which suggests that it is a behavioral model for Li depletion of brain inositol. However, this syndrome has little face validity because seizures are not a component of bipolar disorder. Moreover, other animal species that maintain higher brain inositol levels than mice or rats do not show Li-pilocarpine seizures and a study in humans suggests that humans do not show this syndrome as well. It could be suggested that Li-pilocarpine seizures are an in vivo bioassay for inositol depletion. Recent studies of knockout mice lacking inositol monophosphatase-1 or the sodium myo-inositol transporter-1 found that both these knockout mice given pilocarpine develop limbic seizures as if they had been pre-treated with Li. These mice in addition to such pilocarpine sensitivity have other behaviors such as decreased immobility in the Porsolt forced swim test that suggests that their inositol depletion has Li-like effects. Thus, the Li-pilocarpine seizure model may, despite its lack of face validity, be a biochemical marker for a model of mania treatment in animals.
- Published
- 2007
- Full Text
- View/download PDF
30. SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior.
- Author
-
Shaldubina A, Johanson RA, O'Brien WT, Buccafusca R, Agam G, Belmaker RH, Klein PS, Bersudsky Y, and Berry GT
- Subjects
- Animals, Bipolar Disorder genetics, Bipolar Disorder metabolism, Bipolar Disorder psychology, Genotype, Glycogen Synthase Kinase 3 metabolism, Glycogen Synthase Kinase 3 beta, Inositol deficiency, Lithium therapeutic use, Mice, Behavior, Animal drug effects, Bipolar Disorder drug therapy, Brain metabolism, Inositol metabolism, Lithium pharmacology, Symporters genetics
- Abstract
Two leading hypotheses to explain lithium action in bipolar disorder propose either inositol depletion or inhibition of GSK-3 as mechanisms of action. Behavioral effects of lithium are mimicked in Gsk-3beta+/- mice, but the contribution of inositol depletion to these behaviors has not been tested. According to the inositol depletion hypothesis, lithium-sensitive behavior is secondary to impaired phosphatidylinositol synthesis caused by inositol deficiency. By disrupting the sodium myo-inositol transporter1 gene, SMIT1, we show that depletion of brain myo-inositol in SMIT1+/- mice has no effect on lithium-sensitive behavior. These findings, taken together with our previous work showing that SMIT-/- mice have an even greater depletion of inositol in brain with no reduction in phosphatidylinositol levels, are difficult to reconcile with the current formulation of the inositol depletion hypothesis.
- Published
- 2006
- Full Text
- View/download PDF
31. Inositol deficiency diet and lithium effects.
- Author
-
Shaldubina A, Stahl Z, Furszpan M, Regenold WT, Shapiro J, Belmaker RH, and Bersudsky Y
- Subjects
- Adult, Animals, Antipsychotic Agents administration & dosage, Antipsychotic Agents pharmacokinetics, Bipolar Disorder drug therapy, Bipolar Disorder metabolism, Female, Frontal Lobe metabolism, Humans, Inositol metabolism, Lithium Carbonate administration & dosage, Lithium Carbonate pharmacokinetics, Male, Middle Aged, Rats, Rats, Sprague-Dawley, Severity of Illness Index, Antipsychotic Agents pharmacology, Bipolar Disorder diet therapy, Diet, Frontal Lobe drug effects, Inositol deficiency, Lithium Carbonate pharmacology
- Abstract
Objectives: A major hypothesis explaining the therapeutic effect of lithium (Li) in mania is depletion of inositol via inhibition of inositol monophosphatase. However, inositol is also present in the diet. Restriction of dietary inositol could theoretically enhance the effects of Li., Methods: We used dietary inositol restriction in animal studies and also devised a palatable diet for humans that is 90% free of inositol., Results: Dietary inositol restriction significantly augmented the inositol-reducing effect of Li in rat frontal cortex. Li reduced inositol levels by 4.7%, inositol-deficient diet by 5.1%, and Li plus inositol-deficient diet by 10.8%. However, feeding with the inositol-deficient diet did not enhance the behavioral effect of Li in the Li-pilocarpine seizure model. Fifteen patients participated in an open clinical study of the inositol-deficient diet: six rapid cycling bipolar patients responding inadequately to Li or valproate in different phases of illness; two Li-treated bipolar outpatients with residual symptomatology, and seven inpatient Li-treated bipolar patients in non-responding acute mania. The diet had a major effect in reducing the severity of affective disorder in 10 of the patients within the first 7-14 days of treatment., Conclusion: These results suggest that dietary inositol restriction may be useful in some bipolar patients, but controlled replication is necessary.
- Published
- 2006
- Full Text
- View/download PDF
32. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.
- Author
-
Silverstone PH, McGrath BM, and Kim H
- Subjects
- Animals, Antidepressive Agents therapeutic use, Antipsychotic Agents therapeutic use, Basal Ganglia metabolism, Bipolar Disorder drug therapy, Frontal Lobe metabolism, Gyrus Cinguli metabolism, Humans, Lithium Carbonate therapeutic use, Temporal Lobe metabolism, Valproic Acid therapeutic use, Bipolar Disorder metabolism, Bipolar Disorder physiopathology, Inositol deficiency, Magnetic Resonance Spectroscopy
- Abstract
Objectives: Myo-inositol is an important component of the phosphatidylinositol second messenger system (PI-cycle). Alterations in PI-cycle activity have been suggested to be involved in the pathophysiology and/or treatment of bipolar disorder. More specifically, lithium has been suggested to act primarily by lowering myo-inositol concentrations, the so-called inositol-depletion hypothesis. myo-Inositol concentrations can be measured in vivo with magnetic resonance spectroscopy (MRS)., Methods: The current review primarily examines animal and human MRS studies that evaluated the role of myo-inositol in bipolar illness and treatment., Results: Studies have been carried out in patients who are manic, depressed, and euthymic, both on and off treatment. However, there are several limitations of these studies., Conclusions: The preclinical and clinical MRS findings were generally supportive of the involvement of myo-inositol in bipolar disorder and its treatment. Overall, in bipolar patients who are manic or depressed there are abnormalities in brain myo-inositol concentrations, with changes in frontal and temporal lobes, as well as the cingulate gyrus and basal ganglia. These abnormalities are not seen in either euthymic patients or healthy controls, possibly due to a normalizing effect of treatment with either lithium or sodium valproate. There is also increasing evidence that sodium valproate may also act upon the PI-cycle. Nonetheless, it remains uncertain if these changes in myo-inositol concentration are primary or secondary. Findings regarding the specific inositol-depletion hypothesis are also generally supportive in acutely ill patients, although it is not yet possible to definitively confirm or refute this hypothesis based on the current MRS evidence., (Copyright (c) 2005, Blackwell Munksgaard.)
- Published
- 2005
- Full Text
- View/download PDF
33. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
- Author
-
Harwood AJ
- Subjects
- Animals, Antimanic Agents pharmacology, Bipolar Disorder metabolism, Brain drug effects, Brain physiopathology, Humans, Inositol deficiency, Signal Transduction drug effects, Bipolar Disorder drug therapy, Bipolar Disorder physiopathology, Inositol metabolism, Lithium Compounds pharmacology, Valproic Acid pharmacology
- Abstract
Inositol, a simple six-carbon sugar, forms the basis of a number of important intracellular signaling molecules. Over the last 35 years, a series of biochemical and cell biological experiments have shown that lithium (Li(+)) reduces the cellular concentration of myo-inositol and as a consequence attenuates signaling within the cell. Based on these observations, inositol-depletion was proposed as a therapeutic mechanism in the treatment of bipolar mood disorder. Recent results have added significant new dimensions to the original hypothesis. However, despite a number of clinical studies, this hypothesis still remains to be either proven or refuted. In this review of our current knowledge, I will consider where the inositol-depletion hypothesis stands today and how it may be further investigated in the future.
- Published
- 2005
- Full Text
- View/download PDF
34. Myo-inositol, glucose and zinc status as risk factors for non-syndromic cleft lip with or without cleft palate in offspring: a case-control study.
- Author
-
Krapels IP, Rooij IA, Wevers RA, Zielhuis GA, Spauwen PH, Brussel W, and Steegers-Theunissen RP
- Subjects
- Adult, Case-Control Studies, Cleft Lip blood, Cleft Palate blood, Dietary Supplements, Erythrocytes chemistry, Female, Folic Acid administration & dosage, Humans, Infant, Male, Pregnancy, Prenatal Exposure Delayed Effects, Risk Factors, Blood Glucose analysis, Cleft Lip etiology, Cleft Palate etiology, Inositol deficiency, Pregnancy Complications blood, Zinc deficiency
- Abstract
Objective: To investigate myo-inositol, glucose and zinc status in mothers and their infants on cleft lip with or without cleft palate risk (CLP)., Design: Case-control study., Setting: University Medical Centre Nijmegen, the Netherlands., Population: Eighty-four mothers and their CLP child and 102 mothers and their healthy child., Methods: Venous blood samples were obtained to determine serum myo-inositol and glucose and red blood cell zinc concentrations in mothers and children. Geometric means were calculated and compared between the groups. The blood parameters were dichotomised with cutoff points based on control values,
P90 for glucose concentrations., Main Outcome Measures: Geometric means (P5-P95) and odds ratios (95% confidence intervals)., Results: The CLP children (P= 0.003) and their mothers (P= 0.02) had significantly lower red blood cell zinc concentrations than controls. A low maternal serum myo-inositol concentration (<13.5 micromol/L) and a low red blood cell zinc concentration (<189 micromol/L) increased CLP risk [odds ratio 3.0 (95% CI 1.2-7.4) and 2.0 (95% CI 0.8-4.8), respectively]. Children with low myo-inositol (<21.5 micromol/L ) or low red blood cell zinc concentrations (<118 micromol/L) were more likely to have CLP [odds ratio 3.4 (95% CI 1.3-8.6) and 3.3 (95% CI 1.3-8.0), respectively]. Glucose was not a risk factor for CLP in mothers and children. Maternal and child myo-inositol as well as zinc concentrations were slightly, albeit significantly correlated, r(Pearson)= 0.33 (P= 0.0006) and r(Pearson)= 0.23 (P= 0.01), respectively., Conclusion: This study demonstrates for the first time that zinc and myo-inositol are important in the aetiology of CLP. - Published
- 2004
- Full Text
- View/download PDF
35. Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain.
- Author
-
Berry GT, Buccafusca R, Greer JJ, and Eccleston E
- Subjects
- Animals, Brain metabolism, In Vitro Techniques, Inositol genetics, Inositol metabolism, Mice, Mice, Knockout, Mood Disorders genetics, Mood Disorders metabolism, Phosphatidylinositols analysis, Phosphatidylinositols metabolism, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods, Symporters genetics, Tissue Extracts analysis, Brain drug effects, Inositol deficiency, Lithium pharmacology, Phosphatidylinositols deficiency
- Abstract
The "inositol depletion hypothesis" has been widely held to be the explanation for both the effect of lithium on brain function, apropos of its use in mood disorders, and on the impairment of development and induction of embryonic malformations in diverse organisms. The essence of the hypothesis is that a deficiency in cellular myo-inositol (Ins), secondary to lithium inhibition of inositol monophosphatase and/or multiple inositol polyphosphate phosphatase activities with trapping of Ins as inositol phosphates, leads to a depression of phosphatidylinositol (PtdIns) and a secondary impairment in inositide signaling. However, the ability of relatively low micromolar levels of Ins to reduce mammalian PtdIns synthetase activity in vivo has never been adequately tested. We have generated a lethal murine brain Ins deficiency model and measured PtdIns content using a novel MALDI-TOF MS method. Our results show that in the most severe Ins deficiency ever recorded in a mammal, the brain PtdIns levels do not decrease. We conclude that PtdIns deficiency due to "inositol depletion" is not a mechanism of lithium action in brain, and that Ins plays another unidentified role in the mammalian brain.
- Published
- 2004
- Full Text
- View/download PDF
36. Congenital malformations in offspring of diabetic mothers--animal and human studies.
- Author
-
Eriksson UJ, Cederberg J, and Wentzel P
- Subjects
- Animals, Arachidonic Acid metabolism, Female, Gene Expression Regulation physiology, Genetic Predisposition to Disease, Humans, Hyperglycemia complications, Inositol deficiency, Neural Crest pathology, Pregnancy, Reactive Oxygen Species metabolism, Congenital Abnormalities etiology, Diabetes Complications
- Published
- 2003
- Full Text
- View/download PDF
37. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
- Author
-
Larner J
- Subjects
- Animals, Glycogen Synthase metabolism, Inositol chemistry, Kinetics, Macaca mulatta, Obesity physiopathology, Rats, Stereoisomerism, Blood Glucose physiology, Diabetes Mellitus, Type 1 physiopathology, Inositol deficiency, Inositol physiology, Insulin physiology, Insulin Resistance physiology
- Abstract
In this review we discuss the biological significance of D-chiro-inositol, originally discovered as a component of a putative mediator of intracellular insulin action, where as a putative mediator, it accelerates the dephosphorylation of glycogen synthase and pyruvate dehydrogenase, rate limiting enzymes of non-oxidative and oxidative glucose disposal. Early studies demonstrated a linear relationship between its decreased urinary excretion and the degree of insulin resistance present. When tissue contents, including muscle, of type 2 diabetic subjects were assayed, they demonstrated a more general body deficiency. Administration of D-chiro-inositol to diabetic rats, Rhesus monkeys and now to humans accelerated glucose disposal and sensitized insulin action. A defect in vivo in the epimerization of myo-inositol to chiro-inositol in insulin sensitive tissues of the GK type 2 diabetic rat has been elucidated. Thus, administered D-chiro-inositol may act to bypass a defective normal epimerization of myo-inositol to D-chiro-inositol associated with insulin resistance and act to at least partially restore insulin sensitivity and glucose disposal.
- Published
- 2002
- Full Text
- View/download PDF
38. The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder.
- Author
-
van Calker D and Belmaker RH
- Subjects
- Biological Transport, Active drug effects, Bipolar Disorder metabolism, Carbamazepine pharmacology, Carrier Proteins metabolism, Down-Regulation drug effects, Heat-Shock Proteins metabolism, Humans, Inositol deficiency, Valproic Acid pharmacology, Antimanic Agents pharmacology, Bipolar Disorder drug therapy, Bipolar Disorder physiopathology, Carrier Proteins drug effects, Heat-Shock Proteins drug effects, Inositol metabolism, Lithium Compounds pharmacology, Membrane Proteins, Symporters
- Abstract
The 'inositol-depletion hypothesis' postulates that the therapeutic effects of lithium are due to inhibition of inositol monophosphatase, which leads to depletion of brain cells of myo-inositol and consequently to dampening of phosphoinositide (PI) signaling. This article examines the potential relevance of an alternative mechanism for inositol depletion: inhibition of myo-inositol uptake that proceeds via the sodium/myo-inositol cotransport (SMIT). We discuss recent in vitro experiments that show a pronounced downregulation of SMIT after chronic treatment with lithium, carbamazepine, and valproate at therapeutically relevant concentrations. It is concluded that downregulation of SMIT could represent a common mechanism of action of mood stabilizers.
- Published
- 2000
- Full Text
- View/download PDF
39. Effect of osmolality and myo-inositol deprivation on the transport properties of myo-inositol in primary astrocyte cultures.
- Author
-
Isaacks RE, Bender AS, Kim CY, and Norenberg MD
- Subjects
- Animals, Animals, Newborn, Astrocytes cytology, Astrocytes drug effects, Biological Transport, Active drug effects, Cells, Cultured, Hexoses pharmacology, Hydrogen-Ion Concentration, Inositol metabolism, Inositol physiology, Kinetics, Osmolar Concentration, Osmotic Pressure, Rats, Sodium pharmacology, Time Factors, Astrocytes metabolism, Inositol deficiency
- Abstract
myo-Inositol uptake measured in primary astrocyte cultures was saturable in the presence of Na+ with a Km of 13-18 microM and a Vmax of 9.4 nmoles/mg protein/hour in myo-inositol-fed cells, indicating a high affinity transport system. In myo-inositol-deprived cells, Km was about 53 microM with a Vmax of 13.2 nmoles/mg protein/hour. Decreasing osmolality decreased the Vmax to about 1.9 nmoles/mg protein/hour whereas increasing osmolality increased Vmax about 5-fold, while Kms were essentially unchanged in myo-inositol fed cells. In cells deprived of myo-inositol, Vmax decreased in hypotonic medium and increased in hypertonic medium almost 10-fold, but with more than a doubling of the Km regardless of the osmolality. Glucose (25 mM) inhibited myo-inositol uptake 51% whereas the other hexoses used inhibited uptake much less. Our findings indicate that myo-inositol uptake in astrocytes occurs through an efficient carrier-mediated Na(+)-dependent co-transport system that is different from that of glucose and its kinetic properties are affected by myo-inositol availability and osmotic stress.
- Published
- 1997
- Full Text
- View/download PDF
40. Diabetic embryopathy.
- Author
-
Goto MP and Goldman AS
- Subjects
- Animals, Congenital Abnormalities diagnosis, Female, Fetal Diseases diagnosis, Humans, Inositol deficiency, Pregnancy, Prenatal Diagnosis, Congenital Abnormalities etiology, Fetal Diseases etiology, Pregnancy in Diabetics physiopathology
- Abstract
Infants of diabetic mothers have three to four times the incidence of congenital malformations than that in the general population. These anomalies include defects of the neural tube, heart, urogenital system, skeleton and alimentary tract, and the caudal regression syndrome. The anomalies are considered to result from the maternal metabolic derangements. The mechanism has been suggested to involve a diminished turnover of phosphoinositide or arachidonic acid, or an excess of free oxygen radicals. As most of the anomalies in infants of diabetic mothers occur in the first few weeks of pregnancy, strict glycemic control beginning before conception appears mandated.
- Published
- 1994
- Full Text
- View/download PDF
41. Scyllo-inositol depletion in hepatic encephalopathy.
- Author
-
Lien YH, Michaelis T, Moats RA, and Ross BD
- Subjects
- Autopsy, Brain pathology, Brain Chemistry, Chromatography, High Pressure Liquid, Hepatic Encephalopathy pathology, Humans, Inositol analysis, Inositol deficiency, Magnetic Resonance Imaging, Reference Values, Stereoisomerism, Brain metabolism, Hepatic Encephalopathy metabolism, Inositol metabolism
- Abstract
Cerebral myo-inositol depletion is found in patients with hepatic encephalopathy and can be implicated in the pathogenesis of hepatic encephalopathy. We measured scyllo-inositol, a stereoisomer of myo-inositol, in brain extracts from patients dying in hepatic coma using HPLC and high resolution 1H MRS. The cerebral scyllo-inositol concentration, determined by both methods, in patients without hepatic encephalopathy was 0.41 +/- 0.11 mmol/kg wet weight. It decreased by 73% and 76%, respectively, as measured by HPLC and 1H MRS, in patients with hepatic encephalopathy. These findings indicate that myo-inositol depletion in patients with hepatic encephalopathy is not due to enhanced conversion of myo-inositol to scyllo-inositol or inhibition of myo-inositol transport by scyllo-inositol, but rather to the reduced biosynthesis or transport of both inositols.
- Published
- 1994
- Full Text
- View/download PDF
42. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.
- Author
-
Asplin I, Galasko G, and Larner J
- Subjects
- Adult, Aged, Female, Humans, Hydrogen-Ion Concentration, Inositol analysis, Inositol Phosphates isolation & purification, Male, Middle Aged, Polysaccharides isolation & purification, Pyruvate Dehydrogenase (Lipoamide)-Phosphatase metabolism, Diabetes Mellitus, Type 2 metabolism, Hemodialysis Solutions chemistry, Inositol deficiency, Inositol Phosphates analysis, Insulin Resistance, Muscles chemistry, Polysaccharides analysis
- Abstract
chiro- and myo-Inositols are major components of the two inositol phosphoglycan mediators of insulin action. Previous work in this laboratory has shown hypo-chiro-inositoluria in type II diabetic subjects and decreased chiro-inositol in mediator prepared from skeletal-muscle biopsies of Pima Indian diabetic subjects together with increased myo-inositol concentrations. Because mediator bioactivity was not previously examined, we decided to isolate the two types of insulin mediator from hemodialysate, urine, and autopsy muscle to investigate their bioactivity in control and type II diabetic subjects. Human mediator fractions were isolated at pH 2.0 and pH 1.3 from hemodialysate, urine, and autopsy muscle of type II diabetic subjects and nondiabetic control subjects. Mediators were assayed for bioactivity, and the relative chiro-inositol/myo-inositol concentration ratio was determined for the mediator pH 2.0 samples by using HPLC or GC/MS. Regardless of source, the chiro-inositol-containing mediator pH 2.0 fractions from type II diabetic subjects were markedly less active than those from controls (50% or less) (P < 0.05). In addition, the chiro-inositol/myo-inositol ratio in samples from type II subjects was significantly reduced (1/3-1/9) compared with controls (P < 0.05 for hemodialysate and P < 0.01 for muscle samples). In contrast, no difference in bioactivity was seen in myo-inositol-containing mediator pH 1.3 samples isolated from the same type II diabetic and control subjects. In type II diabetes there is a generalized deficiency of chiro-inositol mediator in the body in terms of both decreased chiro-inositol mediator (pH 2.0) bioactivity and chiro-inositol content.
- Published
- 1993
- Full Text
- View/download PDF
43. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo.
- Author
-
Huang LC, Fonteles MC, Houston DB, Zhang C, and Larner J
- Subjects
- Animals, Cattle, Diabetes Mellitus, Experimental blood, Hydrogen-Ion Concentration, Isomerism, Liver physiology, Male, Muscles drug effects, Protein Kinases isolation & purification, Protein Kinases pharmacology, Rats, Rats, Sprague-Dawley, Reference Values, Sugar Phosphates isolation & purification, Blood Glucose metabolism, Diabetes Mellitus, Experimental metabolism, Glucose metabolism, Glycogen biosynthesis, Inositol analogs & derivatives, Inositol deficiency, Insulin pharmacology, Insulin Resistance physiology, Muscles metabolism, Sugar Phosphates pharmacology
- Abstract
Two insulin mediators, inositol phosphoglycans, were isolated from bovine liver by methods previously developed for rat liver, i.e. chromatography on an AG 1 x 8 ion exchange column and selective elution with HCl at pH 2.0 and 1.3. The pH 2.0 mediator containing D-chiroinositol stimulated pyruvate dehydrogenase phosphatase, whereas the pH 1.3 mediator containing myo-inositol inhibited cAMP-dependent protein kinase. Each mediator was further purified by thin layer and Bio-Gel P4 column chromatography and injected ip into normal fed rats together with [U-14C]glucose. After 2.5 h, diaphragms were removed, and glycogen isolated. Insulin mediators, like insulin, stimulated [U-14C]glucose incorporation into glycogen by 150-160% in a dose-dependent manner in the nanomolar range. Mediators injected iv in the nanomolar range into low dose streptozotocin-diabetic rats decreased plasma glucose 30-45% in 30-60 min, with a return to basal concentrations after 150-180 min. These in vivo insulin-like effects of mediator were observed without changes in serum insulin concentrations. The pH 2.0 mediator was 50-100 times more active (per nmol organic phosphate) than the pH 1.3 mediator in the ip diaphragm glycogenesis assay. Mediator effects on diaphragm were completely blocked by preincubation with an immunopurified inositol phosphoglycan antibody. Both mediators were equally active iv in lowering plasma glucose (per nmol inositol) at concentrations comparable to those of insulin.
- Published
- 1993
- Full Text
- View/download PDF
44. Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys.
- Author
-
Ortmeyer HK, Bodkin NL, Lilley K, Larner J, and Hansen BC
- Subjects
- Analysis of Variance, Animals, Diabetes Mellitus, Type 2 physiopathology, Diabetes Mellitus, Type 2 urine, Female, Glucose Tolerance Test, Hyperinsulinism physiopathology, Hyperinsulinism urine, Hyperinsulinism veterinary, Isomerism, Macaca mulatta, Male, Diabetes Mellitus, Type 2 veterinary, Inositol deficiency, Inositol urine, Insulin Resistance physiology, Monkey Diseases
- Abstract
Previously, we demonstrated that nondiabetic insulin-resistant monkeys had reduced covalent insulin activation of muscle glycogen synthase (GS) compared to normal monkeys and that covalent insulin activation of adipose tissue GS was absent in these monkeys. Covalent insulin activation of muscle and adipose tissue GS in monkeys with impaired glucose tolerance and noninsulin-dependent diabetes (NIDDM) was also absent. As in humans, monkeys with NIDDM have a lower urinary excretion rate of chiroinositol (CI), a component of a putative mediator of insulin action, compared to normal monkeys. To determine whether the urinary excretion rate of CI was related to insulin resistance, which develops naturally in many obese rhesus monkeys, we examined the relationships between 24-h urinary CI excretion rate and 1) whole body insulin-mediated glucose disposal rates (M) and insulin-mediated changes in 2) the skeletal muscle GS activity ratio (sm delta GSAR), 3) the skeletal muscle glycogen phosphorylase activity ratio, and 4) the adipose tissue GS activity ratio (at delta GSAR) in 27 monkeys ranging from normal (n = 12) to insulin resistant (n = 8) to overtly diabetic (n = 7). The urinary CI excretion rate was significantly correlated with M (r = 0.47; P < 0.02), sm delta GSAR (r = 0.38; P < 0.05), skeletal muscle glycogen phosphorylase activity ratio (r = -0.49; P < 0.01), and at delta GSAR (r = 0.46; P < 0.02). The urinary CI excretion rate was also correlated with glucose tolerance (r = 0.39; P < 0.05). There was a wide range of urinary CI excretion rates (0.42-5.17 mumol/day) in monkeys with normal fasting plasma glucose concentrations. However, of the 7 diabetic monkeys, 6 had a urinary CI excretion rate below 2.0 mumol/day, and in the subgroup of 16 monkeys with a urinary CI excretion rate less than 2.0 mumol/day, the associations of urinary CI with M rate (r = 0.65; P < 0.005), glucose tolerance (r = 0.63; P < 0.01), and sm delta GSAR (r = 0.73; P < 0.001) increased in strength and significance. We propose that the urinary CI excretion rate may be 1) a biochemical indicator of both in vivo and in vitro insulin resistance and 2) a noninvasive diagnostic tool with potential for the identification of those individuals at risk for NIDDM and other related diseases with insulin resistance.
- Published
- 1993
- Full Text
- View/download PDF
45. Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys.
- Author
-
Ortmeyer HK, Huang LC, Zhang L, Hansen BC, and Larner J
- Subjects
- Animals, Glucose Tolerance Test, Isomerism, Kinetics, Macaca mulatta, Male, Rats, Rats, Sprague-Dawley, Reference Values, Blood Glucose metabolism, Diabetes Mellitus, Experimental blood, Inositol deficiency, Inositol pharmacology, Insulin blood, Insulin Resistance physiology
- Abstract
The acute effects of administration of D-chiroinositol (D-CI), a component of a putative mediator of insulin action, on plasma glucose were examined in low dose streptozotocin-treated rats and normal rats given a glucose load and the effects on plasma glucose and insulin were determined in five obese rhesus monkeys with varying degrees of spontaneous insulin resistance. Single dose intragastric D-CI (10 mg/kg) administered to streptozotocin-treated rats produced a 30-40% decrease in plasma glucose (P < 0.05) at 30-120 min. Single dose intragastric D-CI (2-15 mg/kg) administered to normal rats 2 h before ip glucose produced a 30-50% decrease (P < 0.05) in plasma glucose. D-CI (10 mg/kg) caused a 50% increase (P < 0.05) in glucose disappearance rates in these rats. Myoinositol (10 mg/kg) was without effect. Intravenously administered single dose D-CI (100 mg/kg) increased both the glucose and insulin disappearance rates by 129 +/- 41% (mean +/- SE; P < 0.06) and 89 +/- 39% (P = 0.01), respectively, in all monkeys between 0-30 min compared to control values. D-CI administration, therefore, lowered elevated plasma glucose in streptozotocin-treated hyperglycemic rats, normal rats given a glucose load, and spontaneously insulin-resistant monkeys with or without noninsulin-dependent diabetes mellitus. Intravenous D-CI also lowered plasma insulin in these monkeys.
- Published
- 1993
- Full Text
- View/download PDF
46. Inositol deficiency increases the susceptibility to neural tube defects of genetically predisposed (curly tail) mouse embryos in vitro.
- Author
-
Cockroft DL, Brook FA, and Copp AJ
- Subjects
- Animals, Culture Media, Culture Techniques, Disease Susceptibility, Mice, Mice, Inbred CBA, Mice, Mutant Strains, Neural Tube Defects embryology, Neural Tube Defects genetics, Inositol deficiency, Neural Tube Defects etiology
- Abstract
Curly tail (ct/ct) mouse embryos, which have a genetic predisposition for neural tube defects (NTD), were grown in culture from the 2-5 somite stage, before the initiation of neurulation, up to the 22-24 somite stage, when closure of the anterior neural tube is normally complete. The embryos were cultured in whole rat serum or in extensively dialysed serum supplemented with glucose, amino acids, and vitamins, with inositol omitted or added at concentrations of 2, 10, 20, and 50 mg/l. Two strains were used as controls; CBA mice, which are related to curly tails, and an unrelated PO stock. It was found that ct/ct embryos were particularly sensitive to inositol deficiency; both they and the CBA embryos showed a similar high incidence of cranial NTD after culture in inositol deficient medium (12/17 and 11/18, respectively). Furthermore, the lowest dose of inositol had no effect on the frequency of head defects in ct/ct mice, though it halved the incidence in CBA embryos. With higher inositol concentrations, the majority of ct/ct embryos completed head closure normally, and their development was generally similar to that obtained in whole serum. PO embryos showed a lower proportion (5/19) of cranial NTD in the inositol deficient medium than the other two strains, and this was further reduced by even the lowest inositol dose.
- Published
- 1992
- Full Text
- View/download PDF
47. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
- Author
-
Brogard JM, Caro-Sampara F, and Blicklé JF
- Subjects
- Aldehyde Reductase metabolism, Animals, Cataract metabolism, Diabetic Nephropathies drug therapy, Diabetic Nephropathies enzymology, Diabetic Neuropathies drug therapy, Diabetic Neuropathies enzymology, Diabetic Retinopathy drug therapy, Diabetic Retinopathy enzymology, Galactose, Humans, Imidazoles therapeutic use, Inositol deficiency, Isoquinolines therapeutic use, Lens, Crystalline metabolism, Naphthalenes therapeutic use, Parasympatholytics therapeutic use, Rats, Aldehyde Reductase antagonists & inhibitors, Diabetes Mellitus, Experimental metabolism, Diabetic Nephropathies metabolism, Diabetic Neuropathies metabolism, Diabetic Retinopathy metabolism, Imidazolidines, Sugar Alcohols metabolism
- Abstract
The evidence of sorbitol excess in the crystalline lens of alloxan-diabetic rats has led to anticipate the role of the enzyme aldose-reductase in the pathogenesis of the diabetic cataract. In addition, a number of experimental works have more recently shown the involvement of myoinositol deficiency, which probably results from the sorbitol accumulation. These metabolic pathways are most likely implicated in the pathogenesis of diabetic neuropathy and perhaps additionally in that of microangiopathy. The synthesis of several aldose-reductase inhibitors (AR inhibitors) confirmed experimentally these hypothesis. By reducing the activity of the enzyme aldose-reductase, these substances suppress the adverse metabolic consequences of polyol accumulation, myositol deficiency and dysfunction of the Na+/K+ ATPase dependent sodium activity. Although different experimentations showed that the AR inhibitors could prevent in animals the development of experimental cataract as well as the early functional or later anatomic abnormalities of the diabetic retinopathy and nephropathy, the clinical trials did not clearly support these experimental results in humans. On the other hand, the AR inhibitors were proved to exhibit some efficacy in the early stage of diabetic neuropathy and in incipient nephropathy where they delay the development of albustix positive proteinuria. However, the benefit of an early treatment with AR inhibitors should be confirmed by long term prospective studies, which could also assess the safety of these drugs in chronic administration.
- Published
- 1992
- Full Text
- View/download PDF
48. Diabetic peripheral neuropathy.
- Author
-
Das AK and Vijayaraghavan MV
- Subjects
- Humans, Inositol deficiency, Inositol metabolism, Sorbitol metabolism, Diabetic Neuropathies classification, Diabetic Neuropathies etiology, Diabetic Neuropathies metabolism
- Abstract
Diabetic neuropathy, a challenging contemporary problem, has a clinical prevalence of 60% problematic peripheral neuropathy occurs in about 20%. Recent concepts in aetiopathogenesis include the role of sorbitol excess and myoinositol depletion in causing deficient Na+/K+ ATPase activity. Sorbitol excess per se may result in intraneuronal oedema. Besides these metabolic hypotheses, theories on endoneurial microcapillary pathology and hypoxia have gained favour. Furthermore, a unifying concept of sorbitol excess with intraneuronal oedema leading to secondary vascular compromise has been suggested. A new research classification linking clinical and laboratory evaluation has been proposed which may serve to unify research results. Quantitative sensory testing, autonomic function testing and electrodiagnosis have been utilised to detect incipient diabetic neuropathy. The benefit of 'tight' glycaemic control has been objectively documented by using laboratory parameters. Oral myoinositol supplementation and gangliosides have produced marginal improvement. The role of intraneuronal oedema in the pathogenesis of diabetic neuropathy and its reversal by aldose reductase inhibitors holds out fresh promise for their use in prevention and treatment.
- Published
- 1991
49. [Diabetic polyneuropathy].
- Author
-
Balabolkin MI and Islambekov RR
- Subjects
- Diabetes Mellitus metabolism, Diabetic Neuropathies diagnosis, Diabetic Neuropathies drug therapy, Humans, Hyperglycemia complications, Inositol deficiency, Inositol metabolism, Peripheral Nerves drug effects, Peripheral Nerves metabolism, Diabetes Complications, Diabetic Neuropathies etiology
- Published
- 1989
50. Myo-inositol deficiency in gerbils: comparative study of the intestinal lipodystrophy in Meriones unguiculatus and Meriones libycus.
- Author
-
Chu SH and Hegsted DM
- Subjects
- Animals, Cocos, Dietary Fats, Female, Intestinal Mucosa metabolism, Phospholipids metabolism, Species Specificity, Starvation metabolism, Triglycerides metabolism, Inositol deficiency, Lipid Metabolism, Whipple Disease etiology
- Abstract
Like Mongolian gerbils (Meriones unguiculatus), Meriones libycus develop an intestinal lipodystrophy due to myo-inositol deficiency. Fat accumulation was observed in the intestine of both species when a myo-inositol-deficient diet containing coconut oil was fed to female gerbils. It began in the duodenum and gradually extended to the entire small intestine. Starvation partially removed the accumulated fats. The efficiency of fat absorption was not affected. Most of the accumulated fats were lauric acid-rich triglyceride with the fatty acid composition reflecting the pattern of the intestinal lymph triglyceride during normal transport of absorbed coconut oil. The ratio of oleic acid to linoleic acid in various intestinal lipids was increased. A marked decrease in all plasma lipid and lipoprotein concentrations, including chylomicron, was also observed. It is assumed that the intestinal fat accumulation resulted from a defect in lymphatic transport of dietary fats.
- Published
- 1980
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.